| |
|
|
|
|
|
 |
| |
|
솔그린12.5주 SOLGREEN INFU.[Aminoacetic Acid(Glycine) , L-alanine , L-arginine , L-aspartic acid , L-glutamic acid , L-histidine , L-leucine
|
|
전문의약품 | 삭제
|
|
|
| |
 |
알림: |
드럭인포에서는 의약품 인터넷 판매를 하지 않습니다. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
유료회원 결재시에는 보다 다양한 약물정보를
이용하실 수 있습니다.
유료정보목록은 전문회원으로
로그인 하시면 확인 가능합니다.
|
|
|
 | 허가정보 |
|
|
| 항목 |
내용 |
청구코드(KD코드)
비급여점검코드
상한금액 |
650900320[A20001451]
[보험코드에 따른 약품기본정보 직접조회]
\0 원/250ml/병(2009.10.01)(현재약가)
\10,918 원/250ml/병(2004.07.01)(변경전약가)
[상병코드조회]
[질병코드조회]
|
| 빠른조회 |
|
| 제품성상 |
무색내지 미황색의 액상제제이다. [제형정보 확인] |
| 포장·유통단위 |
1INFU |
| 포장·코드단위 |
| 약품규격 |
단위 |
포장형태 |
대표코드 |
표준코드 |
비고 |
| 250밀리리터 |
1 바이알 |
병 |
8806509003205 |
8806509003212 |
|
|
| 허가사항 원문조회 |
[허가사항 원문조회]
|
| 효능효과 |
[적응증 별 검색]
다음 상태의 아미노산 보급 : 저단백혈증, 저영양상태, 수술전후
|
| 용법용량 |
* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.
[처방약어]
○성인 : 총 아미노산으로서 체중 kg 당 1일 1～1.5 g을 최대용량으로 정맥 내 점적주사한다.
○투여속도 : 60분간에 총 아미노산으로서 10 g 정도의 농도가 바람직하며, 1분간 25적을 최대용량으로 점적주사함을 원칙으로 한다.
소아, 고령자, 단백요구량이 많은 화상환자 등의 경우는 용량 및 주입속도를 적절히 조절하여 투여하여야 한다.
|
| 금기 |
1) 간성혼수 또는 간성혼수의 우려가 있는 환자
2) 중증의 신장애 환자, 고질소혈증 환자
3) 질소이용을 저해하는 대사 장애가 있는 환자
4) 소모성 심부전증 환자
5) 폐부종 환자
6) 핍뇨증, 무뇨증 환자
7) 고나트륨혈증과 염소혈증 또는 알칼리증 환자(나트륨이온 및 염소이온 함유 시)
8) 방실블럭, 중증근무력증 환자(마그네슘이온 함유 시)
9) 수분 과다 공급 환자
10) 산증 환자
11) 고칼륨혈증 환자(칼륨이온 5 mmol/L 이상 함유 시)
12) 신생아 및 만 2세 이하의 영아
13)심근경색 및 그 병력이 있는 환자 |
| 신중투여 |
1) 울혈성 심부전 환자
2) 나트륨 저류로 인한 부종 환자
3) 간장애, 신장애 환자 |
| 이상반응 |
1) 과민반응 : 드물게 발진 등의 과민 증상이 나타날 수 있으며, 이러한 경우에는 투여를 중지한다.
2) 소화기계 : 때때로 구역, 구토 등의 증상이 나타날 수 있다.
3) 순환기계 : 때때로 흉부불쾌감, 심계항진, 빠른맥(빈맥), 혈압상승 등의 증상이 나타날 수 있다.
4) 대량급속투여할 경우 산증이 나타날 수 있다.
5) 기타 : 가끔 열감, 혈관통, 오한, 발열, 두통, 호흡곤란, 호흡정지, 쇽, 기관지경축, 요로경축이 나타날 수 있다.
6) 말초혈관 확장증이 나타날 수 있다.
7) 다음 대사성 합병증이 나타날 수 있다.
대사성 산증, 저인산혈증, 알칼리증, 고혈당, 당뇨병, 삼투압 이뇨 및 탈수증, 반동성 저혈당, 간효소 상승, 비타민 결핍 및 비타민 과잉, 전해질 불균형, 소아 고암모니아혈증
8) 간부전 및 신부전 환자는 BUN의 상승을 일으킬 수 있다.
9) 간부전 환자는 혈청아미노산의 불균형, 대사성 알칼리증, 전신 질소혈증, 고암모니아혈증, 지각상실, 혼수 등을 일으킬 수 있다.
|
| 상호작용 |
1) 테트라싸이클린과 병용 투여 시 수액아미노산의 단백절약효과를 감소시킬 수 있다.
2) 칼슘염을 정맥주사하면 마그네슘염을 석출시킨다. |
| Off-label Usage |
[조회]
|
|
|
| 정보요약 |
|
|
|
드럭인포 의약품 요약/상세정보
|
|
| 코드 및 분류정보 |
|
|
| 항목 |
내용 |
| 대표코드 |
8806509003205 |
| BIT 약효분류 |
아미노산수액제 (Amino Acid Solutions)
|
| ATC 코드 |
amino acids / B05BA01
[코드분류상세설명]
[ATC코드예측]
|
| 복지부분류코드 |
325 (단백아미노산제제 )
|
| 의약품 바코드정보 |
내용보기
솔그린12.5주/ A20001451
제품규격: 250밀리리터/제품수량: 1/제형: 개
폼목기준코드: 199102056 /대표코드: 8806509003205/표준코드: 8806509003212
구바코드: 8806106300035/비고:-
|
주성분코드 분석 및
중복처방 검토 |
[주성분코드 분석 및 중복처방 검토]
|
| Drugs By Indication |
[전체보기]
|
| Drugs By Classification |
[전체보기]
|
|
|
| 제품정보 |
|
|
|
|
| 복약정보 |
|
|
| 항목 |
내용 |
| LACTmed 바로가기 |
[바로가기]
|
| 약리작용 |
유료정보입니다.
|
| 복약지도 |
유료정보입니다.
|
| 임부에대한투여 |
| * |
전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.
|
|
| |
FDA : C등급
|
|
| * |
상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
|
| * |
반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.
|
|
|
| Pharmacokinetics |
유료정보입니다.
|
| 병용금기 및 연령대금기 근거조회 |
[병용금기 및 연령대금기 근거조회]
|
| 보관상 주의 |
|
| 조제시 주의 |
|
|
|
| 심사정보 |
|
|
|
|
| 학술정보 |
|
|
| 항목 |
내용 |
| DUR (의약품사용평가) |
병용금기 :
고시된 병용금기 내용은 없습니다.
[상호작용/병용금기검색]
연령대금기 :
고시된 연령금기 내용은 없습니다.
[연령대금기상세검색]
|
| 독성정보 |
Acetic acid에 대한 독성정보 : 정보보기
L-Glutamic Acid에 대한 독성정보 : 정보보기
출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
L-alanine에 대한 Mechanism_Of_Action 정보
L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance.
L-arginine에 대한 Mechanism_Of_Action 정보
Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.
L-histidine에 대한 Mechanism_Of_Action 정보
Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints.
L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis.
This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells.
L-leucine에 대한 Mechanism_Of_Action 정보
This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
L-lysine에 대한 Mechanism_Of_Action 정보
Proteins of the herpes simplex virus are rich in L-arginine, and tissue culture studies indicate an enhancing effect on viral replication when the amino acid ratio of L-arginine to L-lysine is high in the tissue culture media. When the ratio of L-lysine to L-arginine is high, viral replication and the cytopathogenicity of herpes simplex virus have been found to be inhibited. L-lysine may facilitate the absorption of calcium from the small intestine.
L-methionine에 대한 Mechanism_Of_Action 정보
The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability.
L-ornithine에 대한 Mechanism_Of_Action 정보
L-Ornithine is metabolised to L-arginine. L-arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of L-arginine in tissues throughout the body. As De novo synthesis of L-arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, L-ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to L-arginine).
|
| Pharmacology |
L-alanine에 대한 Pharmacology 정보
Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids.
L-arginine에 대한 Pharmacology 정보
Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.
L-histidine에 대한 Pharmacology 정보
Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing.
L-leucine에 대한 Pharmacology 정보
An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine
L-lysine에 대한 Pharmacology 정보
Insures the adequate absorption of calcium; helps form collagen ( which makes up bone cartilage & connective tissues); aids in the production of antibodies, hormones & enzymes. Recent studies have shown that Lysine may be effective against herpes by improving the balance of nutrients that reduce viral growth. A deficiency may result in tiredness, inability to concentrate, irritability, bloodshot eyes, retarded growth, hair loss, anemia & reproductive problems.
L-methionine에 대한 Pharmacology 정보
L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity.
L-ornithine에 대한 Pharmacology 정보
A non-essential and nonprotein amino acid, ornithine is critical for the production of the body's proteins, enzymes and muscle tissue. Ornithine plays a central role in the urea cycle and is important for the disposal of excess nitrogen (ammonia). Ornithine is the starting point for the synthesis of many polyamines such as putrescine and spermine. Ornithine supplements are claimed to enhance the release of growth hormone and to burn excess body fat. Ornithine is necessary for proper immune function and good liver function.
|
| Metabolism |
L-histidine에 대한 Metabolism 정보
# Phase_1_Metabolizing_Enzyme:Not Available
L-lysine에 대한 Metabolism 정보
# Phase_1_Metabolizing_Enzyme:Not Available
L-methionine에 대한 Metabolism 정보
# Phase_1_Metabolizing_Enzyme:Glutamine SynthetaseMethylenetetrahydrofolate reductase
|
| Absorption |
L-arginine에 대한 Absorption 정보
Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism.
L-histidine에 대한 Absorption 정보
Absorbed from the small intestine via an active transport mechanism requiring the presence of sodium.
L-lysine에 대한 Absorption 정보
Absorbed from the lumen of the small intestine into the enterocytes by an active transport process
L-methionine에 대한 Absorption 정보
Absorbed from the lumen of the small intestine into the enterocytes by an active transport process.
L-ornithine에 대한 Absorption 정보
Absorbed from the small intestine via a sodium-dependent active transport process
|
| Pharmacokinetics |
L-glutamic acid의 약물동력학자료
- 분포 : 대부분이 골격근에서 합성되고 저장된다.
L-arginine의 약물동력학자료
- 최고 혈중농도 도달 : 경구 : 2시간
- 최대 효과 발현 :
- 당뇨 진단 : 정맥주사 : 20-45 분
혈당의 최고 상승은 20분 후에 나타나며, 인슐린의 최대 상승은 20-30 분 후에 나타나며 glucagon은 30-45 분 후에 나타난다.
- 성장호르몬 보유 진단 : 정맥주사 : 1-2 시간
Arginine 30 g을 30분간 정맥주사 후 성장호르몬의 최대 상승이 약 1-2 시간 후에 나타난다.
- 작용 지속 시간 : 정맥주사 : 1시간
- 흡수 : 위장관에서 잘 흡수됨
- 대사 : 간에서 arginase에 의해 guanidino group이 가수분해되어 urea와 ornithine을 생성한다.
Ornithine은 궁극적으로 glucose 생성에 이용된다.
- 소실 : 신장 : 사구체로 여과되고 신세뇨관으로 재흡수된다.
- 반감기 : 1.2-2 시간
Aminoacetic Acid(Glycine)의 약물동력학자료
- 대사 : Glycine은 단백, creatinine, glycocholic acid, glutathione, uric acid, heme 등의 합성에 관여한다.
체내에서의 분해는 여러단계로 이루어지며 주된 경로는 가역적인 산화적 분해이다.
Serine이 정상적인 분해산물이다.
- 혈장 반감기 : 85분
L-methionine의 약물동력학자료
- 대사 : S-adenosylmethionine을 거쳐 homocysteine으로 전환된다. 그 후 80%가 cystathione, cysteine, taurine, inorganic sulphate로 점차로 대사된다.
|
| Biotransformation |
L-arginine에 대한 Biotransformation 정보
Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized.
L-lysine에 대한 Biotransformation 정보
Hepatic
L-methionine에 대한 Biotransformation 정보
Hepatic
L-ornithine에 대한 Biotransformation 정보
Ornithine undergoes extensive metabolism in the liver to L-arginine, polyamines, and proline, and several other metabolites.
|
| Toxicity |
L-arginine에 대한 Toxicity 정보
Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses.
L-histidine에 대한 Toxicity 정보
ORL-RAT LD50 > 15000 mg/kg, IPR-RAT LD50 > 8000 mg/kg, ORL-MUS LD50 > 15000 mg/kg, IVN-MUS LD50 > 2000 mg/kg; Mild gastrointestinal side effects.
L-lysine에 대한 Toxicity 정보
Not Available
L-methionine에 대한 Toxicity 정보
Doses of L-methionine of up to 250 mg daily are generally well tolerated. Higher doses may cause nausea, vomiting and headache. Healthy adults taking 8 grams of L-methionine daily for four days were found to have reduced serum folate levels and leucocytosis. Healthy adults taking 13.9 grams of L-methionine daily for five days were found to have changes in serum pH and potassium and increased urinary calcium excretion. Schizophrenic patients given 10 to 20 grams of L-methionine daily for two weeks developed functional psychoses. Single doses of 8 grams precipitated encephalopathy in patients with cirrhosis.
L-ornithine에 대한 Toxicity 정보
Oral, rat LD50 = 10000 mg/kg
|
| Drug Interactions |
L-arginine에 대한 Drug_Interactions 정보
Not Available
L-histidine에 대한 Drug_Interactions 정보
Not Available
L-lysine에 대한 Drug_Interactions 정보
Not Available
L-methionine에 대한 Drug_Interactions 정보
Not Available
L-ornithine에 대한 Drug_Interactions 정보
Not Available
|
CYP450
Drug Interaction |
[CYP450 Table직접조회]
|
| Food Interaction |
L-methionine에 대한 Food Interaction 정보
Take with food.
|
| Drug Target |
[Drug Target]
|
| Description |
L-alanine에 대한 Description 정보
A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem]
L-arginine에 대한 Description 정보
An essential amino acid that is physiologically active in the L-form. [PubChem]
L-histidine에 대한 Description 정보
An essential amino acid that is required for the production of histamine. [PubChem]
L-leucine에 대한 Description 정보
An essential branched-chain amino acid important for hemoglobin formation. [PubChem]
L-lysine에 대한 Description 정보
L-Lysine (abbreviated as Lys or K)[1] is an 慣-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG.L-Lysine is a base, as are arginine and histidine. The 琯-amino group often participates in hydrogen bonding and as a general base in catalysis. Common posttranslational modifications include methylation of the 琯-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
L-methionine에 대한 Description 정보
A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. [PubChem]
L-ornithine에 대한 Description 정보
Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. L-Ornithine is a precursor of citrulline and arginine.
|
| Drug Category |
L-alanine에 대한 Drug_Category 정보
Dietary supplementMicronutrientNon-Essential Amino Acids
L-arginine에 대한 Drug_Category 정보
Conditionally Essential Amino AcidsDietary supplementMicronutrient
L-histidine에 대한 Drug_Category 정보
Conditionally Essential Amino AcidsDietary supplementMicronutrient
L-leucine에 대한 Drug_Category 정보
Dietary supplementEssential Amino AcidsMicronutrient
L-lysine에 대한 Drug_Category 정보
Dietary supplementEssential Amino AcidsMicronutrient
L-methionine에 대한 Drug_Category 정보
Dietary supplementEssential Amino AcidsMicronutrient
|
| Smiles String Canonical |
L-alanine에 대한 Smiles_String_canonical 정보
CC(N)C(O)=O
L-arginine에 대한 Smiles_String_canonical 정보
NC(CCCN=C(N)N)C(O)=O
L-histidine에 대한 Smiles_String_canonical 정보
NC(CC1=CN=CN1)C(O)=O
L-leucine에 대한 Smiles_String_canonical 정보
CC(C)CC(N)C(O)=O
L-lysine에 대한 Smiles_String_canonical 정보
NCCCCC(N)C(O)=O
L-methionine에 대한 Smiles_String_canonical 정보
CSCCC(N)C(O)=O
L-ornithine에 대한 Smiles_String_canonical 정보
NCCCC(N)C(O)=O
|
| Smiles String Isomeric |
L-alanine에 대한 Smiles_String_isomeric 정보
C[C@H](N)C(O)=O
L-arginine에 대한 Smiles_String_isomeric 정보
N[C@@H](CCC\N=C(\N)N)C(O)=O
L-histidine에 대한 Smiles_String_isomeric 정보
N[C@@H](CC1=CN=CN1)C(O)=O
L-leucine에 대한 Smiles_String_isomeric 정보
CC(C)C[C@@H](N)C(O)=O
L-lysine에 대한 Smiles_String_isomeric 정보
NCCCC[C@H](N)C(O)=O
L-methionine에 대한 Smiles_String_isomeric 정보
CSCC[C@H](N)C(O)=O
L-ornithine에 대한 Smiles_String_isomeric 정보
NCCC[C@H](N)C(O)=O
|
| InChI Identifier |
L-alanine에 대한 InChI_Identifier 정보
InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1/f/h5H
L-arginine에 대한 InChI_Identifier 정보
InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1/f/h11H,8-9H2
L-histidine에 대한 InChI_Identifier 정보
InChI=1/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/f/h9-10H
L-leucine에 대한 InChI_Identifier 정보
InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/f/h8H
L-lysine에 대한 InChI_Identifier 정보
InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1/f/h9H
L-methionine에 대한 InChI_Identifier 정보
InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/f/h7H
L-ornithine에 대한 InChI_Identifier 정보
InChI=1/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1/f/h8H
|
| Chemical IUPAC Name |
L-alanine에 대한 Chemical_IUPAC_Name 정보
(2S)-2-aminopropanoic acid
L-arginine에 대한 Chemical_IUPAC_Name 정보
(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
L-histidine에 대한 Chemical_IUPAC_Name 정보
(2S)-2-amino-3-(3H-imidazol-4-yl)propanoic acid
L-leucine에 대한 Chemical_IUPAC_Name 정보
2-amino-4-methylpentanoic acid
L-lysine에 대한 Chemical_IUPAC_Name 정보
(2S)-2,6-diaminohexanoic acid
L-methionine에 대한 Chemical_IUPAC_Name 정보
(2S)-2-amino-4-methylsulfanylbutanoic acid
L-ornithine에 대한 Chemical_IUPAC_Name 정보
(2S)-2,5-diaminopentanoic acid
|
| Drug-Induced Toxicity Related Proteins |
LYSINE 의 Drug-Induced Toxicity Related Protein정보
Replated Protein:Tamm-Horsfall protein
Drug:Lysine
Toxicity:persisting acute renal failure .
[바로가기]
METHIONINE 의 Drug-Induced Toxicity Related Protein정보
Replated Protein:NMDA receptor-regulated protein
Drug:methionine
Toxicity:cerebrovascular disease.
[바로가기]
Replated Protein:Cystathionine beta-synthase
Drug:methionine
Toxicity:lipoprotein peroxidation and platelet aggregation.
[바로가기]
Replated Protein:Methylenetetrahydrofolate reductase
Drug:methionine
Toxicity:lipoprotein peroxidation and platelet aggregation.
[바로가기]
|
|
|
| 사용자컨텐츠 |
|
|
|
|
|
-
최근정보수정일 2024-12-05
-
본 수정일 정보는 허가정보 이외의 기타정보 수정일을 의미하므로, 허가정보수정일은 본문에 표기된 날짜를 참조하시기 바랍니다.
|
|
| 알림 |
상세정보는 식품의약품안전처의 제품허가사항을 토대로 작성되었으며 요약정보는 상세정보 및 기타문헌을 기반으로 드럭인포에서 편집한 내용입니다. 제품허가사항의 목차와 다소 상이할 수 있습니다. |
|
| 경고 |
드럭인포 의약학술정보는 식품의약품안전처의 제품허가사항, 학술문헌, 제약회사 제공정보 등을 근거로 작성된 참고 정보입니다.
정보의 정확성을 위해 노력하고 있으나 편집상의 오류, 허가사항 변경, 추가적인 학술연구 또는 임상연구 발표 등으로 인해 발생하는 문제에 대해 드럭인포는
책임을 지지 않습니다. 자세한 내용은 “책임의 한계 및 법적고지”를 참조해 주십시오.
반드시 제조·수입사, 판매사, 의사, 약사에게 최종적으로 확인하시기 바랍니다.
전화: 02-3486-1061 ㅣ 이메일: webmaster@druginfo.co.kr
|
|
아래의 내용을 포함한 전체 데이터를 보시려면
여기로 이동하시기 바랍니다.
병용금기 및 특정연령대 금기 성분
[의약품병용/연령대금기 고시근거로 바로가기] 제목 없음
2008년 8월 1일 약가화일상 8월달 신규등재 및 삭제되는 품목 포함한 병용연령 금기 품목리스트 기준
1. 현재 검색한 제품에 대한 병용금기 제품 존재여부 및 검색
현재 이제품에 대한 병용금기에 해당하는 청구코드별 제품내역 공지내용이 없습니다
2. 연령대금기 존재여부
현재 이제품에 대한 연령금기에 해당하는 청구코드별 공지내용이 없습니다
|
|
|
|
전문/일반
